Murielle M. Véniant

8.9k total citations · 2 hit papers
95 papers, 6.5k citations indexed

About

Murielle M. Véniant is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Murielle M. Véniant has authored 95 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Molecular Biology, 38 papers in Endocrinology, Diabetes and Metabolism and 25 papers in Surgery. Recurrent topics in Murielle M. Véniant's work include Diabetes Treatment and Management (18 papers), Fibroblast Growth Factor Research (14 papers) and Hormonal Regulation and Hypertension (13 papers). Murielle M. Véniant is often cited by papers focused on Diabetes Treatment and Management (18 papers), Fibroblast Growth Factor Research (14 papers) and Hormonal Regulation and Hypertension (13 papers). Murielle M. Véniant collaborates with scholars based in United States, Switzerland and Japan. Murielle M. Véniant's co-authors include Stephen G. Young, Shanaka Stanislaus, Jing Xu, Clarence Hale, David J. Lloyd, Richard Lindberg, Randy Hecht, Constance Zlot, Michelle Chen and Glenn Sivits and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Murielle M. Véniant

93 papers receiving 6.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

2008 974 citations Jing Xu, David J. Lloyd et al. profile →
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

2024 115 citations Murielle M. Véniant, Shu-Chen Lu et al. Nature Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Murielle M. Véniant United States	44	3.7k	1.5k	1.4k	1.2k	1.0k	95	6.5k
Richard Lee United States	32	2.5k 0.7×	968 0.6×	1.7k 1.2×	978 0.8×	998 1.0×	75	5.1k
Lawrence W. Castellani United States	41	2.2k 0.6×	1.3k 0.9×	1.8k 1.3×	766 0.6×	788 0.8×	71	6.6k
Renee Leboeuf United States	49	2.4k 0.7×	1.0k 0.7×	1.7k 1.2×	1.3k 1.1×	662 0.6×	107	6.5k
Ronald E. Law United States	49	4.6k 1.3×	1.1k 0.7×	1.8k 1.3×	1.3k 1.1×	1.4k 1.3×	89	8.2k
Sotirios K. Karathanasis United States	42	3.1k 0.9×	1.5k 1.0×	2.1k 1.5×	831 0.7×	553 0.5×	85	6.2k
Motonobu Anai Japan	44	3.0k 0.8×	1.3k 0.8×	1.4k 1.0×	1.2k 1.0×	382 0.4×	77	5.2k
Catherine Fiévet France	46	3.3k 0.9×	2.3k 1.5×	2.7k 1.9×	1.3k 1.1×	611 0.6×	117	7.4k
Ian P. Salt United Kingdom	36	3.9k 1.1×	1.3k 0.9×	2.2k 1.5×	1.5k 1.2×	617 0.6×	65	5.7k
Hans Häring Germany	43	2.4k 0.6×	1.3k 0.9×	866 0.6×	2.1k 1.8×	820 0.8×	83	5.6k
Marta Letizia Hribal Italy	45	2.3k 0.6×	2.0k 1.3×	1.3k 0.9×	1.3k 1.0×	807 0.8×	124	5.7k

Countries citing papers authored by Murielle M. Véniant

Since Specialization

Citations

This map shows the geographic impact of Murielle M. Véniant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murielle M. Véniant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murielle M. Véniant more than expected).

Fields of papers citing papers by Murielle M. Véniant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murielle M. Véniant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murielle M. Véniant. The network helps show where Murielle M. Véniant may publish in the future.

Co-authorship network of co-authors of Murielle M. Véniant

This figure shows the co-authorship network connecting the top 25 collaborators of Murielle M. Véniant. A scholar is included among the top collaborators of Murielle M. Véniant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murielle M. Véniant. Murielle M. Véniant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Clarissa M., Elizabeth A. Killion, Rola Hammoud, et al.. (2025). GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice. Nature Metabolism. 7(6). 1266–1281. 11 indexed citations

Véniant, Murielle M., Shu-Chen Lu, Larissa Atangan, et al.. (2024). A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nature Metabolism. 6(2). 290–303. 115 indexed citations breakdown →

Killion, Elizabeth A., Michelle Chen, James R. Falsey, et al.. (2020). Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nature Communications. 11(1). 110 indexed citations

Min, Xiaoshan, Junming Yie, Jinghong Wang, et al.. (2020). Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor. mAbs. 12(1). 1710047–1710047. 8 indexed citations

Meng, Qingyuan, et al.. (2020). Hsa-miRNA-23a-3p promotes atherogenesis in a novel mouse model of atherosclerosis. Journal of Lipid Research. 61(12). 1764–1775. 19 indexed citations

Lü, Min, Pingping Li, Gautam Bandyopadhyay, et al.. (2014). Characterization of a Novel Glucokinase Activator in Rat and Mouse Models. PLoS ONE. 9(2). e88431–e88431. 16 indexed citations

Véniant, Murielle M., Clarence Hale, Joan Helmering, et al.. (2012). FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice. PLoS ONE. 7(7). e40164–e40164. 124 indexed citations

Li, Xiaofan, Hongfei Ge, Jennifer Weiszmann, et al.. (2009). Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice. FEBS Letters. 583(19). 3230–3234. 87 indexed citations

Lloyd, David J., Joan Helmering, David Cordover, et al.. (2009). Antidiabetic effects of 11β‐HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obesity and Metabolism. 11(7). 688–699. 28 indexed citations

10.

Anderson, Abraham, Joan Helmering, Todd Juan, et al.. (2009). Pancreatic islet expression profiling in diabetes-prone C57BLKS/J mice reveals transcriptional differences contributed by DBA loci, including Plagl1 and Nnt. PubMed. 2(1). 1–1. 31 indexed citations

11.

Hale, Clarence, Murielle M. Véniant, Zhulun Wang, et al.. (2007). Structural Characterization and Pharmacodynamic Effects of an Orally Active 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor. Chemical Biology & Drug Design. 71(1). 36–44. 26 indexed citations

12.

Cozen, Aaron E., Hideaki Moriwaki, Mary Beth DeYoung, et al.. (2004). Macrophage-Targeted Overexpression of Urokinase Causes Accelerated Atherosclerosis, Coronary Artery Occlusions, and Premature Death. Circulation. 109(17). 2129–2135. 77 indexed citations

13.

Véniant, Murielle M., Sun K. Kim, Patricia Ambroziak, et al.. (2000). Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. Journal of Clinical Investigation. 106(12). 1501–1510. 99 indexed citations

14.

Zlot, Constance, L. M. Flynn, Murielle M. Véniant, et al.. (1999). Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice. Journal of Lipid Research. 40(1). 76–84. 21 indexed citations

15.

Raabe, Martin, Murielle M. Véniant, Constance Zlot, et al.. (1999). Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. Journal of Clinical Investigation. 103(9). 1287–1298. 361 indexed citations

16.

Borén, Jan, Murielle M. Véniant, & Stephen G. Young. (1998). Apo B100-containing lipoproteins are secreted by the heart.. Journal of Clinical Investigation. 101(6). 1197–1202. 107 indexed citations

17.

Véniant, Murielle M., Constance Zlot, Rosemary L. Walzem, et al.. (1998). Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.. Journal of Clinical Investigation. 102(8). 1559–1568. 122 indexed citations

18.

Kim, Edward, Patricia Ambroziak, Murielle M. Véniant, Robert L. Hamilton, & Stephen G. Young. (1998). A Gene-targeted Mouse Model for Familial Hypobetalipoproteinemia. Journal of Biological Chemistry. 273(51). 33977–33984. 15 indexed citations

19.

Véniant, Murielle M., Vincenzo Pierotti, Dale Newland, et al.. (1997). Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.. Journal of Clinical Investigation. 100(1). 180–188. 86 indexed citations

20.

Véniant, Murielle M., Jean‐Paul Clozel, Herbert Kühn, & Martine Clozel. (1993). Protective Effect of Cilazapril on the Cerebral Circulation. Journal of Cardiovascular Pharmacology. 22. S30–35. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact